OSENVELT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OSENVELT (OSENVELT).
Selective allosteric inhibitor of the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose.
| Metabolism | Primarily metabolized via glucuronidation (UGT1A9, UGT2B7) and to a minor extent via CYP3A4 oxidation. |
| Excretion | Renal excretion of unchanged drug accounts for 30-40% of elimination; fecal/biliary excretion accounts for 55-65%. |
| Half-life | Terminal elimination half-life is approximately 12-15 hours, supporting once-daily dosing. |
| Protein binding | 99% bound to plasma albumin. |
| Volume of Distribution | Volume of distribution is 8-10 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is 25-30% due to extensive first-pass metabolism. |
| Onset of Action | Oral administration: clinical effect noted within 1-2 hours post-dose. |
| Duration of Action | Duration of action is approximately 24 hours, allowing once-daily administration. |
200 mg orally once daily with food.
| Dosage form | INJECTABLE |
| Renal impairment | eGFR 15-60 mL/min/1.73 m²: 200 mg every 48 hours; eGFR <15 mL/min or dialysis: not recommended. |
| Liver impairment | Child-Pugh B or C: no dose adjustment required; safety and efficacy not established in severe impairment. |
| Pediatric use | Not approved for use in pediatric patients (age <18 years). |
| Geriatric use | No specific dose adjustment; monitor renal function and adjust per renal guidelines. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OSENVELT (OSENVELT).
| Breastfeeding | No data on excretion in human milk. M/P ratio unknown. Caution advised; consider developmental benefits of breastfeeding vs maternal need for OSENVELT. |
| Teratogenic Risk | No human data available; animal studies not identified. In first trimester, potential for unknown teratogenic risk; avoid unless benefit outweighs risk. Second and third trimesters: no specific fetal risks reported, but use only if clearly needed due to lack of data. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["History of serious hypersensitivity reaction to OSENVELT","Severe renal impairment (eGFR < 30 mL/min/1.73 m²)","End-stage renal disease or dialysis"]
| Precautions | ["Volume depletion","Hypotension","Ketoacidosis","Acute kidney injury","Urosepsis and pyelonephritis","Lower limb amputation","Hypoglycemia with concomitant insulin/sulfonylureas"] |
Loading safety data…
| Monitor maternal vital signs and liver function tests. Fetal monitoring per standard obstetric care; consider growth scans if used long-term. |
| Fertility Effects | No human fertility data; animal studies not available. Potential for hormonal disruption based on drug class; advise preconception counseling. |